VLA1553: Clinical Trials

4 trials of VLA1553, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn, 1 active not recruiting, 1 completed. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Withdrawn 2, Active not recruiting 1, Completed 1

Follow VLA1553: new trials by email Literature Review of VLA1553 trials Research Report on VLA1553

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
VLA1553, Control - Chikungunya Virus Infection
Phase 3WithdrawnValneva Austria GmbH2026-02-062025-12-31
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
VLA1553 - Chikungunya Virus Infection
Phase 3WithdrawnValneva Austria GmbH2024-04-102024-12-02
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
VLA1553 - Chikungunya Virus Infection
Phase 3Active not recruitingValneva Austria GmbH3632021-04-022026-07-09
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
VLA1553, Placebo - Chikungunya Virus Infection
Phase 3CompletedValneva Austria GmbH41282020-09-172023-06-28

Conditions studied

Chikungunya Fever (4)

Sponsors

Valneva Austria GmbH (4)

Countries

United States (2)

Results publications

PMID 37321235, PMID 39146946, PMID 39998495